Clinical trials: AD
Alzheimer Disease
A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers
This study will test two different doses of florbetapir F 18 to determine which dose is best to image amyloid plaques in the brains of Alzheimer's Disease (AD) patients using a positron emission tomography (PET) scanner.
- Trial name
- NCT01565330
- Testing
- florbetapir F 18
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Dementia
Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
This phase IIIb study is intended to implement a consistent treatment way for switching to Exelon transdermal patch from oral formulation of rivastigmine to stress the importance of (1) advantages of transdermal patch over…
- Trial name
- NCT01585272
- Testing
- ENA713
- Where
- 4 sites in Taiwan
- Volunteers
- 121 people
- Sponsor
- Novartis Pharmaceuticals
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Atopic Dermatitis
A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)
The primary objective of the study was to assess the ability of different Dupilumab dose regimens, administered as monotherapy, to maintain the treatment response achieved after 16 weeks of initial treatment with Dupilumab…
- Trial name
- SOLO-CONTINUE (NCT02395133)
- Testing
- Dupilumab
- Volunteers
- 422 people
- Sponsor
- Regeneron Pharmaceuticals
Dementia, Frailty
Pilot Mobile for Dementia and Frailty
In this project, we propose to build on our Stage I formative work (according to the NIH Stage Model for Behavioral Intervention Development), where we developed fully functional prototypes of a mobile intervention aimed at…
- Trial name
- Mindful Meals (NCT05827094)
- Testing
- Mobile app, Usual Care
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Washington
Major Depressive Disorder, Alcohol Use Disorder
Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.
Mirtazapine is a non-SSRI (selective serotonin reuptake inhibitor) medication with a unique structure and mechanism of action. Recent study results suggest that mirtazapine may be more effective and faster acting than other…
- Trial name
- PT-MAD (NCT02185131)
- Testing
- Mirtazapine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pittsburgh
Alcohol Dependence, Post-Traumatic Stress Disorder (PTSD)
Progesterone Effect on Individuals Diagnoses With AD and PTSD.
This is a randomized control trial with an anticipated 36 participants diagnosed with post-traumatic stress disorder (PTSD) and comorbid alcohol dependence. Participants will be randomized to receive either progesterone (200 mg.
- Trial name
- NCT02187224
- Testing
- Progesterone
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yale University
Alzheimer's Disease, Mild Cognitive Impairment
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
- Trial name
- NCT00702143
- Testing
- florbetapir F 18
- Where
- 15 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease, Sleep Disorder
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
The aim of this exploratory randomized, placebo controlled study is to evaluate the efficacy of Circadin® 2mg in patients with mild to moderate Alzheimer Disease (AD) treated with the acetylcholinesterase (AChE) inhibitor.
- Trial name
- NCT00940589
- Testing
- Circadin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 73 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Alzheimer's Disease
Online Caregiver Psychoeducation and Support for Alzheimer's
This study is piloting an internet-based intervention to provide support for caregivers of VA patients with Alzheimer's disease or related memory difficulties (ADRD).
- Trial name
- NCT00416078
- Testing
- caregiver website support, caregiver brief supportive phone calls
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- US Department of Veterans Affairs
Alzheimer Disease, Cognitive Dysfunction
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive and neuropsychiatric symptoms in participants with mild cognitive impairment (MCI) or mild dementia due to…
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
- Trial name
- NCT04602624
- Testing
- SAGE-718
- Where
- 10 sites in United States
- Volunteers
- 26 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Alzheimer Disease
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT02624778
- Testing
- LY3002813
- Where
- 9 sites in United States, Japan
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
To evaluate the tolerability, safety and efficacy of 3-step titration versus 1-step titration of Rivastigmine patch in the Japanese population.
- Trial name
- NCT01614886
- Testing
- Active Comparator, ENA713
- Where
- 50 sites in Japan
- Volunteers
- 216 people
- Sponsor
- Novartis Pharmaceuticals
Suspected Typical Alzheimer's Disease (AD), Suspected Atypical Alzheimer's Disease (AD)
VIdeo Telehealth in ALzheimer's: NeuroPsychology (VITAL-NP)
The overarching goal of this study is to a) assess the feasibility and preliminary validity of home-based delivery of TeleNP to patients with suspected Alzheimer's Disease (AD), referred for cognitive assessments in a Neurology…
- Trial name
- VITAL-NP (NCT05379023)
- Testing
- Face-to-face evaluation (FF), TeleNP evaluation
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- University of Colorado, Denver
Alzheimer's Disease
An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311
To evaluate the long-term safety, tolerability and potential efficacy, patients who previously participated in V203-AD study (NCT02551809) will be eligible to participate in the extension study and will receive 3 or 5 doses of…
- Trial name
- NCT03531710
- Testing
- UB-311
- Where
- 4 sites in Taiwan
- Volunteers
- 34 people
- Sponsor
- United Neuroscience Ltd.
Mild Cognitive Impairment, MCI
Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
A double-blind, placebo-controlled study that aims to investigate the effect of 2-week and 12-week administration of USP methylene blue (MB) on cerebral blood flow, functional connectivity, memory and attention cognitive…
- Conditions
- Mild Cognitive Impairment, MCI, Aging, Alzheimer's Disease
- Trial name
- MB2 (NCT02380573)
- Testing
- Methylene Blue, FD&C Blue # 2, Phenazopyridine hydrochloride
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Alzheimer Disease
Raloxifene for Women With Alzheimer's Disease
This is a multisite pilot randomized trial of raloxifene or placebo for the treatment of women with Alzheimer's disease.
- Trial name
- NCT00368459
- Testing
- raloxifene
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Stanford University
Alzheimer Disease
Tau Screening Study in Patients With Early Symptomatic AD
This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron…
- Trial name
- NCT03322462
- Testing
- Flortaucipir F18, Brain PET Scan
- Where
- 10 sites in United States, Canada
- Volunteers
- 155 people
- Sponsor
- Avid Radiopharmaceuticals
Mild Cognitive Impairment
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
To investigate whether [18F]NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to Alzheimer's disease (AD) from those who do not.
- Trial name
- NAV4-04 (NCT01812213)
- Testing
- [18F]NAV4694
- Where
- 11 sites in United States
- Volunteers
- 76 people
- Sponsor
- Navidea Biopharmaceuticals
Dementia, Cognitive Dysfunction
A Relational Research Recruitment and Engagement Intervention for Cognitive Aging Research
Despite well-documented disparities in Alzheimer's disease and related dementia (AD) prevalence, incidence, treatment, and mortality, individuals from disadvantaged backgrounds (e.g.
- Conditions
- Dementia, Cognitive Dysfunction, Alzheimer Disease, Lewy Body Disease
- Trial name
- NCT05444244
- Testing
- Relational Research Recruitment and Engagement Intervention
- Where
- United States
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison